
MNMD Stock Forecast & Price Target
MNMD Analyst Ratings
Bulls say
Mind Medicine Inc. is advancing toward significant clinical milestones with its lead asset, MM120, which is in Phase 3 studies targeting Generalized Anxiety Disorder (GAD) and has shown strong efficacy in earlier trials. The upcoming readouts from these studies are scheduled for the first half of 2026 and the second half of 2026, indicating a timely progression in the company's developmental timeline. Additionally, the initiation of commercial initiatives and robust engagement with payers highlights the company's proactive approach to market readiness, potentially enhancing its prospects for revenue generation as products progress through clinical development.
Bears say
Mind Medicine Inc. faces significant financial risks due to potential challenges surrounding its patent protections, which could hinder its market success and lead to a decrease in valuation. Furthermore, the company's late-stage clinical developments are susceptible to regulatory approval risks, as failure to secure necessary approvals could adversely affect both Mind Medicine and its collaborators. These factors contribute to a cautious outlook on the company's future financial performance and market viability.
This aggregate rating is based on analysts' research of Mind Medicine MindMed and is not a guaranteed prediction by Public.com or investment advice.
MNMD Analyst Forecast & Price Prediction
Start investing in MNMD
Order type
Buy in
Order amount
Est. shares
0 shares